Reference Detail

Ref Type
PMID
Authors Sheng Yang, Jianliang Yang, Ying Han, Yan Qin, Xiaohong Han, Lihou Dong, Hui Feng, Haifeng Song, Yan Sun, Yuankai Shi
Title A phase 1 trial of JS001, a monoclonal antibody targeting programmed death-1 (PD-1) in patients with advanced or recurrent malignancies.
Journal
Vol
Issue
Date
URL http://abstracts.asco.org/199/AbstView_199_188639.html
Abstract Text J Clin Oncol 35, 2017 (suppl; abstr e14581)

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Therapy Description
JS001 JS001 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response and decreased tumor growth (PMID: 28317872; J Clin Oncol 35, 2017 (suppl; abstr e14581)).
Drug Name Trade Name Synonyms Drug Classes Drug Description
JS001 JS-001|TAB001 Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 48 JS001 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response and decreased tumor growth (PMID: 28317872; J Clin Oncol 35, 2017 (suppl; abstr e14581)).
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable JS001 Phase I Actionable In a Phase I clinical trial, JS001 demonstrated tolerability and preliminary efficacy in patients with advanced malignancies, resulting in complete response in 1/15, partial response in 5/15, and stable disease in 5/15 patients (J Clin Oncol 35, 2017 (suppl; abstr e14581)). detail...